Kronos Bio to be Acquired by Concentra Biosciences for $0.57 Per Share Plus Contingent Value Right

Reuters

昨天

Kronos Bio to be Acquired by Concentra Biosciences for $0.57 Per Share Plus Contingent Value Right

CAMBRIDGE, Mass., May 01, 2025 - Kronos Bio, Inc. (Nasdaq: KRON), a biotechnology company focused on developing small molecule therapeutics for cancer and other diseases, has announced a definitive merger agreement with Concentra Biosciences, LLC. Under the terms of the agreement, Concentra will acquire Kronos Bio for $0.57 in cash per share, along with a contingent value right $(CVR)$. The CVR entitles shareholders to a percentage of the net proceeds from the potential disposition of certain product candidates and cost savings. The merger is anticipated to close by mid-2025, following a tender offer to acquire all outstanding shares of Kronos Bio Common Stock. Kronos Bio's Board of Directors has endorsed the acquisition as beneficial for shareholders.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kronos Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9442754-en) on May 01, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2532072479"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2532072479\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2532072479?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-01 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2532072479","market":"nz","top_or_hot":-1,"title":"Kronos Bio to be Acquired by Concentra Biosciences for $0.57 Per Share Plus Contingent Value Right","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Kronos Bio to be Acquired by Concentra Biosciences for $0.57 Per Share Plus Contingent Value Right\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CAMBRIDGE, Mass., May 01, 2025 - <a href=\"https://laohu8.com/S/KRON\">Kronos Bio, Inc.</a> (Nasdaq: KRON), a biotechnology company focused on developing small molecule therapeutics for cancer and other diseases, has announced a definitive merger agreement with Concentra Biosciences, LLC. Under the terms of the agreement, Concentra will acquire Kronos Bio for $0.57 in cash per share, along with a contingent value right <a href=\"https://laohu8.com/S/CVR\">$(CVR)$</a>. The CVR entitles shareholders to a percentage of the net proceeds from the potential disposition of certain product candidates and cost savings. The merger is anticipated to close by mid-2025, following a tender offer to acquire all outstanding shares of Kronos Bio Common Stock. Kronos Bio's Board of Directors has endorsed the acquisition as beneficial for shareholders.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kronos Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9442754-en) on May 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kronos Bio to be Acquired by Concentra Biosciences for $0.57 Per Share Plus Contingent Value Right</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKronos Bio to be Acquired by Concentra Biosciences for $0.57 Per Share Plus Contingent Value Right\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-05-01 20:30</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Kronos Bio to be Acquired by Concentra Biosciences for $0.57 Per Share Plus Contingent Value Right\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CAMBRIDGE, Mass., May 01, 2025 - <a href=\"https://laohu8.com/S/KRON\">Kronos Bio, Inc.</a> (Nasdaq: KRON), a biotechnology company focused on developing small molecule therapeutics for cancer and other diseases, has announced a definitive merger agreement with Concentra Biosciences, LLC. Under the terms of the agreement, Concentra will acquire Kronos Bio for $0.57 in cash per share, along with a contingent value right <a href=\"https://laohu8.com/S/CVR\">$(CVR)$</a>. The CVR entitles shareholders to a percentage of the net proceeds from the potential disposition of certain product candidates and cost savings. The merger is anticipated to close by mid-2025, following a tender offer to acquire all outstanding shares of Kronos Bio Common Stock. Kronos Bio's Board of Directors has endorsed the acquisition as beneficial for shareholders.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kronos Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9442754-en) on May 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KRON","symbol_name":"Kronos Bio, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250501:nNDL8JbRYx:1","article_id":"2532072479","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2532072479","pubTimestamp":1746102638,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"CAMBRIDGE, Mass., May 01, 2025 - Kronos Bio, Inc. , a biotechnology company focused on developing small molecule therapeutics for cancer and other diseases, has announced a definitive merger agreement with Concentra Biosciences, LLC. Under the terms of the agreement, Concentra will acquire Kronos Bio for $0.57 in cash per share, along with a contingent value right . The CVR entitles shareholders to a percentage of the net proceeds from the potential disposition of certain product candidates and cost savings. The merger is anticipated to close by mid-2025, following a tender offer to acquire all outstanding shares of Kronos Bio Common Stock. Kronos Bio's Board of Directors has endorsed the acquisition as beneficial for shareholders.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KRON":"Kronos Bio, Inc.","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4112":"金融交易所和数据","BK4585":"ETF&股票定投概念","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4505":"高瓴资本持仓","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4139":"生物科技","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4588":"碎股","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","NDAQ":"纳斯达克OMX交易所","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC"},"translate_title":"Kronos Bio将被Concentra Biosciences以每股0.57美元外加或有价值权收购","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KRON":0.9,"NDAQ":0.9},"content_text":"Kronos Bio to be Acquired by Concentra Biosciences for $0.57 Per Share Plus Contingent Value Right\n    \n\n        CAMBRIDGE, Mass., May 01, 2025 - Kronos Bio, Inc. (Nasdaq: KRON), a biotechnology company focused on developing small molecule therapeutics for cancer and other diseases, has announced a definitive merger agreement with Concentra Biosciences, LLC. Under the terms of the agreement, Concentra will acquire Kronos Bio for $0.57 in cash per share, along with a contingent value right $(CVR)$. The CVR entitles shareholders to a percentage of the net proceeds from the potential disposition of certain product candidates and cost savings. The merger is anticipated to close by mid-2025, following a tender offer to acquire all outstanding shares of Kronos Bio Common Stock. Kronos Bio's Board of Directors has endorsed the acquisition as beneficial for shareholders.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kronos Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9442754-en) on May 01, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation,merge","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}